The group’s Braftovi/Mektovi combo shows the potential of a targeted approach in colorectal cancer, so where is the competition?
Peloton Therapeutics’ approach to fighting kidney tumours has apparently convinced Merck & Co, which is to pay $1.05bn for the company on the back of relatively…
Until now all PD-(L)1 blockers were assumed to have broadly similar activity, with any differences being put down to trial design; the latest renal cancer data could…
In the Keynote-426 study Merck & Co’s Keytruda looks to have blasted Opdivo out of the water, showing a 47% reduction in risk of death versus Sutent.
Intercept Pharmaceuticals and the whole Nash field await Ocaliva’s pivotal readout.
Merck & Co awaits full Keynote-426 data with Keytruda plus Inlyta, while Seattle Genetics looks beyond Adcetris with enfortumab vedotin.
Shutdown or no, drug reviews are still under way, giving the sector something to look forward to as 2019 kicks off.
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.
Vast amounts of data were presented at the Esmo meeting over the weekend. Here is a roundup of Vantage’s analysis of the most crucial trials.